Raising revenue forecasts typically signals to investors that a company is performing well and expects stronger financial results than previously anticipated. For Castle Biosciences, this upward revision in revenue guidance for FY23 suggests that the company is experiencing robust demand for its products or services, which could lead to increased investor confidence and potentially a rise in stock price in the short term.